We strongly believe that it is essential to look for mechanisms of resistance to treat patients with TKI that target ALK to better understand the pathophysiology and the way ALK-rearranged NSCLC adapt to different therapeutics [120,121]. This evidence concerns the gene ALK and non-small cell lung carcinoma.